Last updated: 12/10/2020 13:30:04
A single-centre, randomised, double-blind, placebo-controlled, dose-ascending, parallel-group study to evaluate the safety, tolerability, extra-pulmonary pharmacodynamics and systemic pharmacokinetics of GSK159802 administered once daily for 28 days in healthy male subjects.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
EU CT Number
Not applicable
Trial status
Other
Other
Trial overview
Official title: A single-centre, randomised, double-blind, placebo-controlled, dose-ascending, parallel-group study to evaluate the safety, tolerability, extra-pulmonary pharmacodynamics and systemic pharmacokinetics of GSK159802 administered once daily for 28 days in healthy male subjects.
Trial description: A single-centre, randomised, double-blind, placebo-controlled, dose-ascending, parallel-group study to evaluate the safety, tolerability, extra-pulmonary pharmacodynamics and systemic pharmacokinetics of GSK159802 administered once daily for 28 days in healthy male subjects.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
2006-15-11
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Pulmonary Disease, Chronic Obstructive
Product
GSK159802
Collaborators
Not applicable
Study date(s)
September 2006 to November 2006
Type
Interventional
Phase
1
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
Study documents
Clinical study report
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Other
Actual primary completion date
2006-15-11
Actual study completion date
2006-15-11
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website